Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sales of Fujisawa's Funguard Well Ahead of Initial Forecast
December 29, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 29, 2003
- Sales of GE Pravastatin Having Difficulties: Elmed Eisai
December 29, 2003
- PRESS SEMINAR
December 29, 2003
- Kuraya Sanseido to Merge with ATOL, Everlth to Form MEDICEO
December 29, 2003
- DIAGNOSTIC NEWS IN BRIEF
December 29, 2003
- Wholesalers' Profits May Fall 30% This Fiscal Year: Mr Kimura of CR&C
December 29, 2003
- MEDICAL DEVICE NEWS IN BRIEF
December 29, 2003
- FPMAJ to Introduce Bar Code System Starting from Bio-derived Products
December 29, 2003
- WORLD NEWS IN BRIEF
December 29, 2003
- Quintiles' CSO Business Growing Rapidly
December 29, 2003
- The Value of New Medicines
December 29, 2003
- BUSINESS NEWS IN BRIEF
December 29, 2003
- MEETING
December 29, 2003
- Medical Fees Remain Unchanged
December 29, 2003
- Meet the Leaders (28)
December 29, 2003
- 5 Ingredients/9 Products Included in NHI List
December 29, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 29, 2003
- Proposed Basic Policy for FY2004 Medical Fee Revision Approved
December 29, 2003
- Semi-annual Business Results
December 22, 2003
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…